J.B.A.G. Haanen
-
- Cancer Immunotherapy and Biomarkers 9
- Cutaneous Melanoma Detection and Management 7
- Colorectal Cancer Treatments and Studies 3
- CAR-T cell therapy research 2
-
- Immunotherapy and Immune Responses 3
-
- Melanoma and MAPK Pathways 6
-
- Health Systems, Economic Evaluations, Quality of Life 2
-
- Computational Drug Discovery Methods 2
- Co-authors
- Maria KuiperMarta López‐YurdaArend G. J. AalbersLorenzo F. FanchiMoritz MaasMonique E. van LeerdamMarleen KokGeerard L. Beets
- Partner nations
- NetherlandsAustraliaGermany
In The Last Decade
J.B.A.G. Haanen
15 papers receiving 92 citations
Peers
Comparison fields: 5 of 25
- Oncology 86
- Pathology and Forensic Medicine 28
- Immunology 25
- Immunology and Allergy 4
- Molecular Biology 28
Countries citing papers authored by J.B.A.G. Haanen
This map shows the geographic impact of J.B.A.G. Haanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.B.A.G. Haanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.B.A.G. Haanen more than expected).
Fields of papers citing papers by J.B.A.G. Haanen
This network shows the impact of papers produced by J.B.A.G. Haanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.B.A.G. Haanen. The network helps show where J.B.A.G. Haanen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside J.B.A.G. Haanen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 1 | |
| 4 | 2022 | 3 | |
| 5 | 2022 | 1 | |
| 6 | 2021 | 7 | |
| 7 | 2021 | 3 | |
| 8 | 2018 | 46 | |
| 9 | 2018 | 7 | |
| 10 | 2018 | 2 | |
| 11 | 2017 | 3 | |
| 12 | Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study | 2016 | 2 |
| 13 | 2015 | 4 | |
| 14 | 2015 | 2 | |
| 15 | Clinical response to ipilimumab: Effect of systemic corticosteroids used to manage immune-related adverse events (irAEs) | 2010 | 5 |
| 16 | Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. | 2008 | 7 |
About J.B.A.G. Haanen
J.B.A.G. Haanen is a scholar working on Oncology, Immunology and Allergy and Immunology, having authored 16 papers that have together received 94 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (9 papers), Cutaneous Melanoma Detection and Management (7 papers), Melanoma and MAPK Pathways (6 papers), Immunotherapy and Immune Responses (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), CAR-T cell therapy research (2 papers) and Computational Drug Discovery Methods (2 papers). The work is most often cited by research in Oncology (86 citations), Pathology and Forensic Medicine (28 citations) and Immunology (25 citations). J.B.A.G. Haanen has collaborated with scholars based in Netherlands, Australia and Germany. Frequent co-authors include Maria Kuiper, Marta López‐Yurda, Arend G. J. Aalbers, Lorenzo F. Fanchi, Moritz Maas, Monique E. van Leerdam, Marleen Kok, Geerard L. Beets, Myriam Chalabi and Cecile Grootscholten. Their work appears in journals such as Annals of Oncology, Value in Health, Melanoma Research, European Journal of Cancer and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.